Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, B-Cell, Marginal Zone

ClinicalTrials.gov lists 863 trials for Lymphoma, B-Cell, Marginal Zone or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 80.

MeSH D018442 Neoplasms Neoplasm C04 C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 275 Phase 1/2 Phase 1/2 94 Phase 2 Phase 2 294 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 66 Phase 4 Phase 4 3 Not applicable Not applicable 59 Observational Observational 66 Phase 1 Phase 1 275 Phase 1/2 Phase 1/2 94 Phase 2 Phase 2 294 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 66 Phase 4 Phase 4 3 Not applicable Not applicable 59 Observational Observational 66

Trials per phase (log scale)

2 more sections with rows

863 of the 863 trials are tagged with Lymphoma, B-Cell, Marginal Zone itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, B-Cell, Marginal Zone report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, B-Cell, Marginal Zone trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 45

1990: 3 trials (Not applicable 1, Phase 2 2) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 3, Phase 1 1) 1993: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1994: 3 trials (Phase 2 1, Phase 1 2) 1995: 8 trials (Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 1996: 13 trials (Observational 2, Not applicable 1, Phase 2 5, Phase 1 5) 1997: 28 trials (Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 9) 1998: 33 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 10) 1999: 45 trials (Not applicable 4, Phase 3 6, Phase 2 10, Phase 1/2 3, Phase 1 22) 2000: 39 trials (Not applicable 4, Phase 3 3, Phase 2 18, Phase 1/2 4, Phase 1 10) 2001: 26 trials (Not applicable 1, Phase 3 5, Phase 2 8, Phase 1/2 2, Phase 1 10) 2002: 28 trials (Observational 1, Not applicable 4, Phase 3 3, Phase 2 6, Phase 1/2 1, Phase 1 13) 2003: 26 trials (Observational 1, Not applicable 5, Phase 3 1, Phase 2 8, Phase 1/2 3, Phase 1 8) 2004: 38 trials (Observational 1, Not applicable 4, Phase 3 2, Phase 2 14, Phase 1/2 3, Phase 1 14) 2005: 44 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2 19, Phase 1/2 8, Phase 1 7) 2006: 32 trials (Observational 4, Not applicable 3, Phase 3 4, Phase 2 10, Phase 1/2 2, Phase 1 9) 2007: 42 trials (Other 1, Observational 3, Not applicable 3, Phase 3 6, Phase 2 12, Phase 1/2 2, Phase 1 15) 2008: 39 trials (Observational 9, Not applicable 1, Phase 3 4, Phase 2 10, Phase 1/2 5, Phase 1 10) 2009: 31 trials (Other 1, Observational 6, Not applicable 3, Phase 3 1, Phase 2 7, Phase 1/2 4, Phase 1 9) 2010: 28 trials (Observational 3, Not applicable 3, Phase 2 11, Phase 1/2 3, Phase 1 8) 2011: 21 trials (Not applicable 2, Phase 3 1, Phase 2 9, Phase 1/2 4, Phase 1 5) 2012: 15 trials (Not applicable 2, Phase 2 5, Phase 1/2 2, Phase 1 6) 2013: 17 trials (Observational 1, Phase 3 2, Phase 2 5, Phase 1/2 3, Phase 1 6) 2014: 21 trials (Not applicable 1, Phase 3 2, Phase 2 3, Phase 1/2 6, Phase 1 9) 2015: 10 trials (Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 4) 2016: 16 trials (Observational 2, Not applicable 2, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 4) 2017: 29 trials (Observational 1, Phase 3 1, Phase 2 13, Phase 1/2 7, Phase 1 7) 2018: 18 trials (Observational 2, Phase 2 5, Phase 1/2 3, Phase 1 8) 2019: 18 trials (Not applicable 1, Phase 3 1, Phase 2 9, Phase 1/2 3, Phase 1 4) 2020: 25 trials (Observational 1, Phase 2 9, Phase 1/2 5, Phase 1 10) 2021: 29 trials (Observational 2, Phase 3 3, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 10) 2022: 21 trials (Observational 3, Phase 3 2, Phase 2 7, Phase 1/2 2, Phase 1 7) 2023: 23 trials (Observational 4, Phase 4 1, Phase 3 3, Phase 2 3, Phase 1/2 2, Phase 1 10) 2024: 22 trials (Observational 7, Not applicable 1, Phase 3 1, Phase 2 8, Phase 1 5) 2025: 31 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 16, Phase 1/2 1, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 24
2025 31
2024 22
2023 23
2022 21
2021 29
2020 25
2019 18
2018 18
2017 29

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 31 trials starting in 2026 and about 29 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 71 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 615 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, B-Cell, Marginal Zone trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 275
Phase 1/2 94
Phase 2 294
Phase 2/3 4
Phase 3 66
Phase 4 3
Not applicable 59
Observational 66
Expanded access 1
Unknown 1

How many Lymphoma, B-Cell, Marginal Zone trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 14
Recruiting 88
Enrolling by invitation 2
Active, not recruiting 50
Completed 492

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, B-Cell, Marginal Zone trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 80
National Institutes of Health Clinical Center (CC) 13

Which drugs are being tested for Lymphoma, B-Cell, Marginal Zone? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 151
Cytoxan 132
Busulfan 45

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 103
Peripheral blood stem cell transplantation 80
Filgrastime (G-CSF) 58
Mofetil Mycophenolate 57
Cyclosporine 0.05% 54

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, B-Cell, Marginal Zone trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 325 43
Febrile neutropenia 289 50
Death 238 20
Pyrexia 225 26
Platelet count decreased 172 25

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, B-Cell, Marginal Zone? (98)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN 2025 Yes
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. British journal of haematology 2025 Yes
An Occult Primary Thymic Mucosa-Associated Lymphoid Tissue Lymphoma With Sjögren's Syndrome Revealed by CXCR4 Targeted <sup>68</sup>Ga-Pentixafor PET/CT. Journal of cellular and molecular medicine 2025 Yes
Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy. Blood 2024 Yes
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024 Yes

Showing 5 of 98 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Marginal zone lymphoma Annual incidence 1-9 / 100 000 France Not stated Exact
Marginal zone lymphoma Point prevalence 1-9 / 100 000 Europe Not stated Exact
Marginal zone lymphoma Annual incidence 1-9 / 100 000 France Not stated Exact
Marginal zone lymphoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Marginal zone lymphoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Marginal zone lymphoma 300912 Exact Orphadata Science knowledge files, Product 1
Marginal zone lymphoma 300912 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages